Sernova (STU:PSH) ROCE % : 0.00% (As of Jul. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Sernova ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sernova's annualized ROCE % for the quarter that ended in Jul. 2024 was 0.00%.

Sernova ROCE % Historical Data

The historical data trend for Sernova's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova ROCE % Chart

Sernova Annual Data

Trend

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

ROCE %

Get a 7-Day Free Trial

-98.26

-104.16

-42.06

-65.47

-122.20

Sernova Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
ROCE %	Get a 7-Day Free Trial															-144.11	-263.00	-457.50	-	-

Sernova ROCE % Calculation

Sernova's annualized ROCE % for the fiscal year that ended in Oct. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Oct. 2023 )		(A: Oct. 2022 )		(A: Oct. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Oct. 2023 )		(A: Oct. 2022 )		(A: Oct. 2023 )
	=	-26.911	/	( ( (38.916 - 3.515)	+	(15.268 - 6.625) )	/ 2 )
	=	-26.911	/	( (35.401	+	8.643)	/ 2 )
	=	-26.911	/	22.022
	=	-122.20 %

Sernova's ROCE % of for the quarter that ended in Jul. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jul. 2024 )		(Q: Apr. 2024 )		(Q: Jul. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jul. 2024 )		(Q: Apr. 2024 )		(Q: Jul. 2024 )
	=	-19.312	/	( ( (8.02 - 11.415)	+	(5.013 - 13.116) )	/ 2 )
	=	-19.312	/	( ( -3.395	+	-8.103 )	/ 2 )
	=	-19.312	/	-5.749
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Jul. 2024) EBIT data.

Sernova (STU:PSH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sernova ROCE % Related Terms

Thank you for viewing the detailed overview of Sernova's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sernova Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Corp (STU:PSH) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

SEOVF:USA PSH:Germany PSH:Germany SVA:Canada

Address

700 Collip Circle, The Stiller Centre, Suite 114, London, ON, CAN, N6G 4X8

Website

https://www.sernova.com

Sernova Corp is a clinical-stage company developing products for the treatment of chronic debilitating diseases. The company is engaged in the research and development of its proprietary Cell Pouch and associated technologies including immune-protected therapeutic cells. The Cell Pouch is is a scalable, implantable medical device designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells, which then release proteins, hormones or other factors into the bloodstream for the long-term treatment of multiple chronic diseases such as type 1 diabetes, hypothyroid disease, and rare diseases such as hemophilia A.